Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Should You Buy the Pop in Novo Nordisk Stock?

Novo Nordisk (NVO) shares rallied more than 6% today after the Food and Drug Administration (FDA) approved Wegovy for treating metabolic dysfunction-associated steatohepatitis (MASH).  

Investors are cheering NVO shares also because the pharma giant said cash-paying U.S. customers can now access its blockbuster diabetes drug, Ozempic, at a massive discount ($499 per month). 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.